152 related articles for article (PubMed ID: 36591532)
1. Diagnosis and management of AL amyloidosis due to B-cell non-Hodgkin lymphoma.
Berkowitz C; Dittus C
Front Oncol; 2022; 12():915420. PubMed ID: 36591532
[TBL] [Abstract][Full Text] [Related]
2. Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia).
Bou Zerdan M; Valent J; Diacovo MJ; Theil K; Chaulagain CP
Adv Hematol; 2022; 2022():1182384. PubMed ID: 35096069
[TBL] [Abstract][Full Text] [Related]
3. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
4. Two distinct syndromes of lymphoma-associated AL amyloidosis: a case series and review of the literature.
Telio D; Bailey D; Chen C; Crump M; Reece D; Kukreti V
Am J Hematol; 2010 Oct; 85(10):805-8. PubMed ID: 20872959
[TBL] [Abstract][Full Text] [Related]
5. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome.
Wechalekar AD; Lachmann HJ; Goodman HJ; Bradwell A; Hawkins PN; Gillmore JD
Blood; 2008 Nov; 112(10):4009-16. PubMed ID: 18708629
[TBL] [Abstract][Full Text] [Related]
6. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
Vitolo U; Ferreri AJ; Montoto S
Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
[TBL] [Abstract][Full Text] [Related]
7. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.
Gertz MA; Kyle RA; Noel P
J Clin Oncol; 1993 May; 11(5):914-20. PubMed ID: 8487054
[TBL] [Abstract][Full Text] [Related]
8. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
[TBL] [Abstract][Full Text] [Related]
9. Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience.
la Torre A; Reece D; Crump M; Atenafu EG; Chen C; Prica A; Kukreti V
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e946-e959. PubMed ID: 34384733
[TBL] [Abstract][Full Text] [Related]
10. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma.
Korell F; Schönland S; Schmitt A; Jansen M; Farid K; Müller-Tidow C; Dreger P; Schmitt M; Hegenbart U
Biomark Res; 2023 Oct; 11(1):91. PubMed ID: 37838756
[TBL] [Abstract][Full Text] [Related]
11. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
12. Cancer risk in amyloidosis patients in Sweden with novel findings on non-Hodgkin lymphoma and skin cancer.
Hemminki K; Li X; Försti A; Sundquist J; Sundquist K
Ann Oncol; 2014 Feb; 25(2):511-8. PubMed ID: 24406424
[TBL] [Abstract][Full Text] [Related]
13. Serum Paraprotein Is Associated with Adverse Prognostic Factors and Outcome, across Different Subtypes of Mature B-Cell Malignancies-A Systematic Review.
Cox MC; Esposito F; Postorino M; Venditti A; Di Napoli A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760410
[TBL] [Abstract][Full Text] [Related]
14. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM).
Kyle RA; Dispenzieri A; Kumar S; Larson D; Therneau T; Rajkumar SV
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):74-6. PubMed ID: 21454195
[TBL] [Abstract][Full Text] [Related]
15. Composite monoclonal B-cell lymphocytosis and MYD88 L265P-positive lymphoplasmacytic lymphoma in a patient with IgM light chain amyloidosis: Case report.
Oishi N; Inoue T; Odate T; Mochizuki K; Ohashi K; Kirito K; Kondo T
Pathol Int; 2020 Jul; 70(7):458-462. PubMed ID: 32323419
[TBL] [Abstract][Full Text] [Related]
16. Endomyocardial biopsy with co-localization of a lymphoplasmacytic lymphoma and AL amyloidosis.
Leguit RJ; Vink A; de Jonge N; Minnema MC; Oerlemans MIF
Cardiovasc Pathol; 2021; 53():107348. PubMed ID: 34038803
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentation and treatment responses in IgM-related AL amyloidosis.
Sissoko M; Sanchorawala V; Seldin D; Sworder B; Angelino K; Broce M; Berk J; Sloan JM
Amyloid; 2015; 22(4):229-35. PubMed ID: 26488936
[TBL] [Abstract][Full Text] [Related]
18. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
Palladini G; Foli A; Russo P; Milani P; Obici L; Lavatelli F; Merlini G
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):143-5. PubMed ID: 21454217
[TBL] [Abstract][Full Text] [Related]
19. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T
PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040
[TBL] [Abstract][Full Text] [Related]
20. Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia.
Ozaki S; Abe M; Wolfenbarger D; Weiss DT; Solomon A
Clin Immunol Immunopathol; 1994 May; 71(2):183-9. PubMed ID: 8181187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
